Your session is about to expire
Plavix vs Heparin
Introduction
For patients with cardiovascular diseases or those at risk of blood clot formation, certain drugs that affect the coagulation pathways in the body and prevent platelet aggregation are essential for preventing life-threatening events like heart attacks and strokes. Plavix and Heparin are two such drugs that are commonly prescribed for these conditions. They each impact different aspects of the clotting cascade but both have anti-clotting effects in patients.
Plavix, also known as clopidogrel, is a P2Y12 platelet inhibitor which impedes the binding of ADP to its platelet receptor thereby inhibiting platelet activation and aggregation. This makes it particularly useful in reducing the risk of heart attack or stroke in people who already have an increased risk due to other medical conditions.
Heparin, on the other hand, enhances antithrombin III activity which neutralizes thrombin — a key enzyme involved in blood coagulation — thus preventing fibrin formation. It's often used acutely during hospitalizations when rapid onset anticoagulation is needed.
Plavix vs Heparin Side By Side
| Attribute | Plavix | Heparin |
|---|---|---|
| Brand Name | Plavix | Heparin |
| Contraindications | Should not be used with aspirin, NSAIDs, warfarin, or any drug that affects platelet function. Caution in patients with recent surgery. | Increased risk of significant bleeding complications, especially around surgeries. Not advised for patients with uncontrolled high blood pressure, recent surgery, or certain types of stroke. |
| Cost | Around $300 for 30 tablets of 75 mg or $0.20 - $2/day for generic | Up to $40 per vial for brand name; generic varies, typically more expensive than clopidogrel |
| Generic Name | Clopidogrel | Heparin |
| Most Serious Side Effect | Signs of bleeding, allergic reactions, Thrombotic Thrombocytopenic Purpura (TTP) | Unusual bleeding or bruising, allergic reactions, thrombocytopenia, osteoporosis with long-term use |
| Severe Drug Interactions | Aspirin, NSAIDs, warfarin, drugs affecting platelet function | Drugs that increase bleeding risk, such as aspirin, NSAIDs, and other anticoagulants |
| Typical Dose | 75 mg/day for adults; for acute coronary syndrome, an initial dose of 300mg followed by 75 mg/day in combination with aspirin | Initial IV bolus dose of 5000 units, followed by continuous IV infusion. Maintenance dosage ranges from 10000 to 20000 units every 24 hours, adjusted based on aPTT levels. |
What is Plavix?
Clopidogrel (known by the brand name Plavix) is a type of drug called an antiplatelet, which prevents platelets in your blood from sticking together and forming a blood clot. It was first approved by the FDA in 1997. Plavix works by blocking certain receptors on platelets, making them less likely to form clots, thus reducing the risk of heart attack or stroke. This medication is typically prescribed for people with recent history of heart attack or stroke, or those diagnosed with peripheral artery disease.
Heparin, on the other hand, is an anticoagulant that slows down how fast your body makes clots. Unlike Clopidogrel that alters platelet function to prevent clot formation, Heparin directly interferes with the process of clot formation itself.
While both drugs are used for similar purposes - preventing harmful clots - they have different ways of achieving this goal and can be used in different patient situations depending upon individual health circumstances and risks.
What conditions is Plavix approved to treat?
Plavix, also known as clopidogrel, is approved for the treatment and prevention of various heart-related conditions:
- Acute coronary syndrome (ACS), including unstable angina and non-ST-elevation myocardial infarction (NSTEMI)
- ST-elevation myocardial infarction (STEMI) in patients who are to be managed medically
- Prevention of atherothrombotic events in patients with recent stroke or established peripheral arterial disease.
How does Plavix help with these illnesses?
Plavix helps to manage the risk of heart disease and stroke by reducing the formation of blood clots. It does this by preventing platelets, a type of blood cell, from sticking together and forming potentially dangerous clots. Platelets play a crucial role in hemostasis, helping to stop bleeding at the site of injured blood vessels. In certain conditions where clotting is too high, such as after a heart attack or stroke, preventing these platelets from aggregating can reduce the chances of future cardiovascular events. Plavix accomplishes this by inhibiting an enzyme known as P2Y12 ADP receptor on the platelet surface which prevents activation and aggregation. Therefore, through its antiplatelet effect, Plavix can limit further complications in patients with cardiovascular diseases.
On similar lines but with different mechanism Heparin works as an anticoagulant that helps prevent thrombosis—a condition where blood clots form inside veins and arteries—by enhancing natural substances in your body that inhibit clot formations. Unlike Plavix which targets platelets directly , heparin increases activity of antithrombin III thus leading to reduced ability for plasma proteins to carry out coagulation process thereby inhibiting overall clot formation.
What is Heparin?
Heparin is a blood thinner, or anticoagulant, that inhibits clotting factors in the blood to prevent the formation of clots. It does so by activating an enzyme called antithrombin III which neutralizes thrombin and other clot-promoting enzymes. Heparin was first discovered in 1916 and has been used medically since the 1930s. As it's not an antiplatelet drug like Plavix (clopidogrel), it doesn't work by blocking platelets from sticking together to form clots; instead, its action on coagulation factors makes its mode of operation distinct. Its side-effect profile is also different, particularly because it can cause bleeding complications if not monitored carefully - a common effect of anticoagulants such as heparin but less so with antiplatelet drugs like Plavix. The effects on preventing clot formation can be beneficial for patients who are at risk for heart attacks or strokes due to blood clots, especially those who do not respond well to "typical" antiplatelet drugs such as Plavix.
What conditions is Heparin approved to treat?
Heparin is a frequently prescribed anticoagulant that has been given the green light by regulatory authorities for the treatment of:
- Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism
- Preventing clots in blood vessels before or after certain surgeries
- Prevention and treatment of other conditions related to problematic clotting.
How does Heparin help with these illnesses?
Heparin is a potent anticoagulant that plays an essential role in preventing clot formation and extension, promoting blood flow within the vessels. It acts by enhancing the activity of antithrombin III, an enzyme inhibitor that blocks several other enzymes involved in coagulation. This process helps to prevent thrombus or clot formation, which could lead to complications such as stroke or pulmonary embolism. Unlike Plavix, which inhibits platelet aggregation thereby reducing their ability to form clots, heparin has a more direct impact on the coagulation cascade itself. Since it works differently from drugs like Plavix (which are antiplatelet medications), heparin is often used when immediate anticoagulation effects are required or in situations where a patient does not respond well to typical antiplatelet agents.
How effective are both Plavix and Heparin?
Both clopidogrel (Plavix) and heparin are commonly used anticoagulant medications that serve to prevent blood clotting, but they operate through different mechanisms of action. Clopidogrel is an orally administered drug that inhibits the adhesion of platelets in the blood, thereby reducing the likelihood of clot formation. Heparin, on the other hand, is usually given via injection or intravenously and works by activating an enzyme called antithrombin III which blocks thrombin - a key factor in blood clotting.
The effectiveness of Plavix was evaluated in a 2001 clinical trial where it showed significant benefits over aspirin alone in preventing cardiovascular events such as stroke or heart attack among patients at risk. Its safety profile also indicated fewer instances of gastrointestinal bleeding compared to those taking Aspirin.
In contrast, Heparin has been widely used since World War II for its immediate anti-clotting effects making it particularly useful during surgeries or other medical interventions where rapid anticoagulation is needed. However, prolonged use can lead to complications such as increased risk for osteoporosis and low platelet count.
In terms of prescription trends both drugs have their unique applications; while Plavix is typically prescribed for long-term management due to its oral administration convenience and efficacy over time , heparin's swift onset makes it ideal for acute care settings like post-operative scenarios or immediately after a heart attack/stroke event. It should be noted though that these two drugs are often not directly comparable because they're typically employed under distinct clinical circumstances based on patient needs.
Related trials for plavix and heparin
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Plavix typically prescribed?
Oral dosages of Plavix, also known as clopidogrel, usually start at 75 mg/day for adults to prevent blood clots after a recent heart attack or stroke and in people with peripheral vascular disease. For acute coronary syndrome, an initial dose of 300mg may be used followed by 75 mg/day in combination with aspirin. On the other hand, Heparin is given via injection or intravenously (IV). The dosage varies greatly depending on the condition being treated and is often determined based on body weight. Regular monitoring is necessary while receiving Heparin due to its narrow therapeutic index and risk of excessive bleeding. Always follow your doctor's prescriptions strictly when taking either medication.
At what dose is Heparin typically prescribed?
Heparin therapy is typically initiated with an intravenous (IV) bolus dose of 5000 units, followed by continuous IV infusion. The maintenance dosage ranges from 10000 to 20000 units every 24 hours, depending on the patient's response and condition. Monitoring is necessary for adjusting the doses; this usually involves checking activated partial thromboplastin time (aPTT) levels at regular intervals, typically every six hours initially. If there's no sufficient anticoagulant effect after initial dosing, further increments in dosage can be made under close medical supervision until desired therapeutic outcomes are achieved.
What are the most common side effects for Plavix?
Common side effects of Plavix (Clopidogrel) can include:
- Easy bruising
- Minor bleeding
- Diarrhea, stomach pain or indigestion
- Headache or dizziness
On the other hand, Heparin might cause side effects like:
- Irritation, pain, redness, warmth at the injection site
- Bleeding and bruising more easily
- Nausea and vomiting
- Skin rash and itching
It's important to remember that each individual may respond differently to these medications. If you experience any severe symptoms such as heavy bleeding or signs of an allergic reaction (e.g., difficulty breathing), seek immediate medical attention.
Are there any potential serious side effects for Plavix?
While both Plavix and Heparin are anticoagulants designed to prevent blood clots, they do have potential side effects that can be serious.
With Plavix, you should look out for:
- Signs of bleeding such as spontaneous bruising or bleeding, black or tarry stools, red or pink urine, coughing up blood or vomit that looks like coffee grounds.
- Allergic reactions including rashes; itching/swelling (especially of the face/tongue/throat); severe dizziness; difficulty breathing.
- Symptoms related to a condition called Thrombotic Thrombocytopenic Purpura (TTP) which include fever, confusion and slurred speech.
On the other hand with Heparin:
- Unusual bleeding and bruising
- Blood in urine or stool
- Extreme thigh or lower back pain
- Difficulty breathing
- Slowed heart rate
Always remember if any of these symptoms appear while using either medication consult your healthcare professional immediately.
What are the most common side effects for Heparin?
Common side effects of Heparin may include:
- Bleeding more easily, including from minor cuts and nosebleeds
- Bruising or discoloration at the injection site
- Thrombocytopenia (low platelet count)
- Nausea or vomiting
- Irritation, pain, redness, warmth, or skin changes where the medicine was injected. It is important to note that while these symptoms can be a nuisance, they are typically not severe. However, if you're taking Heparin and notice unexplained bleeding or bruising under the skin that gets worse rather than better over time—it's crucial to speak with your healthcare provider immediately as this could indicate a serious reaction.
Are there any potential serious side effects for Heparin?
While Heparin is an effective anticoagulant, it can sometimes cause severe side effects. It's important to be aware of potential warning signs which may include:
- An allergic reaction; symptoms could include hives, difficulty breathing, and swelling in the face or throat.
- Unusual bleeding or bruising that comes on suddenly (including nosebleeds, blood in urine or stools)
- Sudden severe headaches or migraines
- Dizziness and/or confusion
- Vision changes including blurred vision
- Shortness of breath
- Heartbeat abnormalities such as racing heartbeats or irregular pulse.
If you experience any of these symptoms while taking heparin, seek immediate medical attention.
Contraindications for Plavix and Heparin?
Both Plavix and Heparin, as with most other anticoagulant medications, may increase the risk of excessive bleeding. If you notice blood in your urine or stools, unusual bruising or bleeding from the gums or nose, please seek immediate medical attention.
Neither Plavix nor Heparin should be used if you are taking certain other medicines like aspirin, NSAIDs (Non-steroidal anti-inflammatory drugs), warfarin or any drug that affects platelet function. Always tell your physician which medications you are taking; these will require a period of clearance from the system to prevent dangerous interactions with Plavix and Heparin.
In addition to this cautionary measure, both medications have their own specific considerations. For instance, individuals using heparin should be wary about its use around surgeries due to increased risk of significant bleeding complications. Similarly, people prescribed plavix who have had recent surgery must inform their doctor before beginning treatment.
How much do Plavix and Heparin cost?
For the brand name versions of these drugs:
- The price for 30 tablets of Plavix (75 mg) averages around $300, which works out to approximately $10/day.
- The cost for a vial of Heparin (5,000 units/0.25 ml), used in hospital settings and not typically sold at pharmacies, varies significantly but could be as high as $40 per vial. Depending on your dosage needs, this could result in higher daily costs.
Therefore, if you require frequent doses of Heparin throughout the day, brand-name Plavix may prove less expensive on a per-day treatment basis. Again, it is crucial to remember that cost should never be the only factor when choosing between these medications.
As far as generic versions are concerned:
- Clopidogrel bisulfate (the generic equivalent of Plavix) can range from approximately $0.20 - $2/day based on varying dosages and package sizes.
- Generic heparin injections tend to vary greatly due to different formulations and strengths available; however, they are generally more expensive than clopidogrel due to being administered in a controlled environment like hospitals or clinics rather than home use.
Popularity of Plavix and Heparin
Clopidogrel, also known as Plavix, was estimated to have been prescribed to about 33 million people in the US in 2019. It is an oral antiplatelet drug that's used by individuals with heart disease and poor circulation to prevent clots and reduce the risk of a stroke or heart attack. Clopidogrel accounted for around 10% of all cardiovascular prescriptions in the US.
Heparin, on the other hand, is delivered intravenously or subcutaneously and often used acutely in hospital settings rather than being prescribed for daily use at home. It was administered to nearly 5 million hospitalized patients across America within the same year. Heparin accounts for just under 2% of overall anticoagulant administrations within hospitals. Over recent years, there has been an increased preference towards direct oral anticoagulants (DOACs), yet heparin remains a mainstay due its rapid onset/offset of action and reversibility.
Conclusion
Both Plavix (clopidogrel) and heparin have a long history of usage in patients with cardiovascular diseases, being backed by numerous clinical studies and meta-analyses indicating that they are more effective than placebo treatments for preventing blood clot formation. Both drugs may sometimes be used together under careful medical supervision, but this is subject to careful consideration by a physician as they can increase the risk of bleeding. Due to their different mechanisms of action, with clopidogrel inhibiting platelet aggregation and heparin acting as an anticoagulant, they tend to be prescribed under different circumstances.
Clopidogrel is often given orally as a long-term treatment after heart attack or stroke whereas heparin is usually administered intravenously or subcutaneously for short-term management during hospital stays or certain procedures. Both medications are available in generic form which represents significant cost savings especially for patients who must pay out of pocket.
The side effect profile between the two drugs varies; both carry risks relating to excessive bleeding, though there may be other side effects such as allergic reactions (more common with heparin) and gastrointestinal upset (more common with clopidogrel). Patients on these medications need to closely monitor any unusual bruising or bleeding and should seek medical help immediately if severe bleeding occurs.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Lyseng-Williamson, K. A., & Plosker, G. L. (2006). Clopidogrel. PharmacoEconomics. Springer Science and Business Media LLC.http://doi.org/10.2165/00019053-200624070-00009
- Saha, S., Berglund, M., Sylvén, C., Gordon, A., & Agewall, S. (2008, January). Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. International Journal of Cardiology. Elsevier BV.http://doi.org/10.1016/j.ijcard.2006.11.136
- Reilly, B. M., Raschke, R., Srinivas, S., & Nieman, T. (1993, October). Intravenous heparin dosing. Journal of General Internal Medicine. Springer Science and Business Media LLC.http://doi.org/10.1007/bf02599634
- Cakar, M., Kocayigit, I., Aydin, E., Demirci, H., & Gunduz, H. (2012). Clopidogrel-induced spontaneous pectoral hematoma. Indian Journal of Pharmacology. Medknow.http://doi.org/10.4103/0253-7613.99342
- Ned, R. M. (2010, September 20). Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availabilityApplication: Pharmacogenomics. PLoS Currents. Public Library of Science (PLoS).http://doi.org/10.1371/currents.rrn1180
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J.-P. R., … Antman, E. M. (2008, April). Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. The Lancet. Elsevier BV.http://doi.org/10.1016/s0140-6736(08)60422-5
- Walenga, J. M., & Bick, R. L. (1998, May). Heparin-Induced Thrombocytopenia, Paradoxical Thromboembolism, And Other Side Effects Of Heparin Therapy. Medical Clinics of North America. Elsevier BV.http://doi.org/10.1016/s0025-7125(05)70015-8
- Harr, T., Scherer, K., Tsakiris, D. A., & Bircher, A. J. (2006, May 5). Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy. Wiley.http://doi.org/10.1111/j.1398-9995.2006.01063.x
- Comin, J., & Kallmes, D. (2011, December). Clopidogrel (Plavix). American Journal of Neuroradiology. American Society of Neuroradiology (ASNR).http://doi.org/10.3174/ajnr.a2913
- Gresele, P., Busti, C., & Paganelli, G. (2011, December 2). Heparin in the Prophylaxis and Treatment of Venous Thromboembolism and Other Thrombotic Diseases. Handbook of Experimental Pharmacology. Springer Berlin Heidelberg.http://doi.org/10.1007/978-3-642-23056-1_9
- Kim, B.-H., Kim, J.-R., Lim, K. S., Shin, H.-S., Yoon, S. H., Cho, J.-Y., … Yu, K.-S. (2012, October 2). Comparative Pharmacokinetics/Pharmacodynamics of Clopidogrel Besylate and Clopidogrel Bisulfate in Healthy Korean Subjects. Clinical Drug Investigation. Springer Science and Business Media LLC.http://doi.org/10.1007/s40261-012-0007-3
- Caldeira, D., Fernandes, R. M., Costa, J., David, C., Sampaio, C., & Ferreira, J. J. (2013, April). Branded Versus Generic Clopidogrel in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/fjc.0b013e31827e5c60